Concepts (302)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aspartic Acid | 15 | 2013 | 65 | 3.990 |
Why?
|
| Receptors, IgG | 15 | 2021 | 94 | 2.430 |
Why?
|
| Immunoglobulin Gm Allotypes | 15 | 2022 | 103 | 1.780 |
Why?
|
| Brain | 12 | 2022 | 2176 | 1.600 |
Why?
|
| Canavan Disease | 6 | 2022 | 6 | 1.250 |
Why?
|
| Cytomegalovirus | 6 | 2016 | 63 | 1.190 |
Why?
|
| Dipeptides | 6 | 2013 | 89 | 1.180 |
Why?
|
| Immunoglobulin G | 13 | 2022 | 481 | 1.150 |
Why?
|
| Organophosphate Poisoning | 2 | 2017 | 6 | 1.130 |
Why?
|
| Acetates | 6 | 2023 | 74 | 1.100 |
Why?
|
| Acetate-CoA Ligase | 2 | 2023 | 2 | 0.910 |
Why?
|
| Amidohydrolases | 7 | 2022 | 60 | 0.890 |
Why?
|
| Genotype | 16 | 2021 | 786 | 0.870 |
Why?
|
| Rats | 14 | 2020 | 5300 | 0.810 |
Why?
|
| Neuroblastoma | 3 | 2014 | 109 | 0.800 |
Why?
|
| Cytomegalovirus Infections | 5 | 2016 | 69 | 0.790 |
Why?
|
| Acetyltransferases | 4 | 2013 | 49 | 0.790 |
Why?
|
| Acetyl Coenzyme A | 3 | 2016 | 10 | 0.750 |
Why?
|
| Cytoplasm | 3 | 2010 | 155 | 0.740 |
Why?
|
| Pralidoxime Compounds | 2 | 2017 | 3 | 0.720 |
Why?
|
| Kynurenine | 2 | 2020 | 36 | 0.720 |
Why?
|
| Quinolinic Acid | 1 | 2020 | 11 | 0.710 |
Why?
|
| NAD | 2 | 2020 | 73 | 0.710 |
Why?
|
| Central Nervous System | 3 | 2011 | 107 | 0.700 |
Why?
|
| Animals | 28 | 2023 | 20881 | 0.700 |
Why?
|
| Cholinesterase Reactivators | 2 | 2017 | 2 | 0.690 |
Why?
|
| Obidoxime Chloride | 2 | 2017 | 2 | 0.690 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2020 | 2083 | 0.670 |
Why?
|
| Immunoglobulin Km Allotypes | 7 | 2021 | 34 | 0.650 |
Why?
|
| Gene Expression Regulation | 2 | 2023 | 1293 | 0.640 |
Why?
|
| Neurons | 6 | 2010 | 881 | 0.640 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 110 | 0.620 |
Why?
|
| Viral Core Proteins | 2 | 2008 | 12 | 0.610 |
Why?
|
| Isoflurane | 1 | 2017 | 16 | 0.600 |
Why?
|
| Anesthetics, Inhalation | 1 | 2017 | 21 | 0.600 |
Why?
|
| Viral Proteins | 3 | 2016 | 150 | 0.590 |
Why?
|
| Mitochondria | 4 | 2014 | 643 | 0.590 |
Why?
|
| Lipid Metabolism | 3 | 2010 | 186 | 0.580 |
Why?
|
| Antidotes | 1 | 2017 | 21 | 0.580 |
Why?
|
| Membrane Glycoproteins | 3 | 2021 | 370 | 0.580 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2015 | 26 | 0.530 |
Why?
|
| Enzyme Therapy | 1 | 2015 | 4 | 0.530 |
Why?
|
| Immunity, Humoral | 7 | 2022 | 42 | 0.530 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 40 | 0.520 |
Why?
|
| Body Weight | 1 | 2017 | 554 | 0.500 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 160 | 0.490 |
Why?
|
| Myelin Sheath | 4 | 2010 | 115 | 0.490 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 17 | 0.470 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2016 | 381 | 0.460 |
Why?
|
| Aging | 2 | 2017 | 911 | 0.420 |
Why?
|
| Cell Nucleus | 3 | 2013 | 305 | 0.420 |
Why?
|
| Immunoglobulins | 3 | 2017 | 97 | 0.420 |
Why?
|
| Methamphetamine | 2 | 2013 | 132 | 0.410 |
Why?
|
| Administration, Intranasal | 3 | 2017 | 88 | 0.400 |
Why?
|
| Breast Neoplasms | 6 | 2018 | 1536 | 0.390 |
Why?
|
| Disease Models, Animal | 7 | 2022 | 2550 | 0.390 |
Why?
|
| Hepacivirus | 3 | 2008 | 90 | 0.370 |
Why?
|
| Coenzyme A Ligases | 1 | 2010 | 25 | 0.370 |
Why?
|
| Myelin Basic Protein | 2 | 2011 | 62 | 0.360 |
Why?
|
| Riluzole | 1 | 2010 | 2 | 0.360 |
Why?
|
| Triacetin | 1 | 2010 | 1 | 0.350 |
Why?
|
| Acetic Acid | 1 | 2010 | 14 | 0.350 |
Why?
|
| Graft vs Host Disease | 1 | 2012 | 163 | 0.350 |
Why?
|
| Male | 23 | 2021 | 37321 | 0.350 |
Why?
|
| Brain Injuries | 2 | 2010 | 268 | 0.350 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2010 | 128 | 0.340 |
Why?
|
| Humans | 42 | 2022 | 68618 | 0.320 |
Why?
|
| Mice | 8 | 2023 | 8474 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 756 | 0.320 |
Why?
|
| Amino-Acid N-Acetyltransferase | 1 | 2008 | 1 | 0.320 |
Why?
|
| Microsomes | 1 | 2008 | 31 | 0.320 |
Why?
|
| Hepatitis C Antibodies | 1 | 2008 | 19 | 0.310 |
Why?
|
| Tryptophan | 2 | 2020 | 65 | 0.310 |
Why?
|
| Protein Binding | 6 | 2016 | 1027 | 0.280 |
Why?
|
| Tritium | 2 | 2017 | 101 | 0.280 |
Why?
|
| Cell Line, Tumor | 6 | 2013 | 1851 | 0.280 |
Why?
|
| Liver | 2 | 2023 | 1118 | 0.270 |
Why?
|
| Antipsychotic Agents | 1 | 2008 | 247 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 511 | 0.260 |
Why?
|
| Biological Availability | 2 | 2016 | 79 | 0.260 |
Why?
|
| Mucin-1 | 2 | 2017 | 35 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1745 | 0.260 |
Why?
|
| Hippocampus | 2 | 2020 | 471 | 0.250 |
Why?
|
| Schizophrenia | 2 | 2017 | 206 | 0.250 |
Why?
|
| Viral Envelope Proteins | 2 | 2015 | 43 | 0.250 |
Why?
|
| Mutation | 1 | 2010 | 1213 | 0.250 |
Why?
|
| Alleles | 8 | 2021 | 386 | 0.240 |
Why?
|
| Oligodendroglioma | 2 | 2013 | 18 | 0.230 |
Why?
|
| Genes, Immunoglobulin | 2 | 2014 | 56 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 2791 | 0.220 |
Why?
|
| Lipogenesis | 1 | 2023 | 9 | 0.220 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2020 | 10 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 84 | 0.210 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 778 | 0.210 |
Why?
|
| Herpesvirus 1, Human | 1 | 2022 | 30 | 0.210 |
Why?
|
| Immunoglobulin kappa-Chains | 2 | 2013 | 30 | 0.200 |
Why?
|
| Fatty Acids | 1 | 2023 | 222 | 0.200 |
Why?
|
| Energy Metabolism | 3 | 2010 | 222 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2016 | 786 | 0.190 |
Why?
|
| Ketones | 1 | 2020 | 24 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 83 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 72 | 0.180 |
Why?
|
| Pokeweed Mitogens | 1 | 2020 | 9 | 0.180 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2020 | 39 | 0.180 |
Why?
|
| Gerbillinae | 1 | 2020 | 156 | 0.170 |
Why?
|
| Female | 18 | 2021 | 38074 | 0.170 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2020 | 46 | 0.170 |
Why?
|
| Immunity | 1 | 2020 | 67 | 0.170 |
Why?
|
| Parkinson Disease | 1 | 2022 | 272 | 0.170 |
Why?
|
| Spleen | 1 | 2020 | 301 | 0.170 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 105 | 0.160 |
Why?
|
| Carbon Radioisotopes | 2 | 2009 | 34 | 0.160 |
Why?
|
| Neuroprotective Agents | 2 | 2013 | 317 | 0.160 |
Why?
|
| Antibody Formation | 4 | 2021 | 93 | 0.160 |
Why?
|
| HIV Infections | 2 | 2019 | 791 | 0.160 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2013 | 346 | 0.160 |
Why?
|
| Case-Control Studies | 6 | 2022 | 1553 | 0.160 |
Why?
|
| HIV Antibodies | 1 | 2018 | 28 | 0.150 |
Why?
|
| Epistasis, Genetic | 2 | 2018 | 32 | 0.150 |
Why?
|
| Paraoxon | 1 | 2017 | 4 | 0.150 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 455 | 0.150 |
Why?
|
| Cell Fractionation | 2 | 2008 | 34 | 0.150 |
Why?
|
| Acetylation | 3 | 2016 | 94 | 0.150 |
Why?
|
| Trigeminal Ganglion | 1 | 2017 | 5 | 0.150 |
Why?
|
| Olfactory Bulb | 1 | 2017 | 14 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 283 | 0.150 |
Why?
|
| Afferent Pathways | 1 | 2017 | 31 | 0.150 |
Why?
|
| Antibody Affinity | 3 | 2016 | 26 | 0.150 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 58 | 0.150 |
Why?
|
| Young Adult | 7 | 2021 | 5717 | 0.140 |
Why?
|
| Cell Movement | 1 | 2020 | 630 | 0.140 |
Why?
|
| Melatonin | 1 | 2016 | 39 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2018 | 215 | 0.140 |
Why?
|
| Serotonin | 1 | 2016 | 144 | 0.130 |
Why?
|
| Acetylcholinesterase | 1 | 2016 | 19 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2016 | 50 | 0.130 |
Why?
|
| Amygdala | 1 | 2017 | 159 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 4655 | 0.130 |
Why?
|
| Immune Tolerance | 1 | 2016 | 114 | 0.130 |
Why?
|
| Fetus | 1 | 2016 | 157 | 0.130 |
Why?
|
| Mice, Knockout | 2 | 2013 | 1692 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 565 | 0.130 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 1174 | 0.130 |
Why?
|
| Adult | 12 | 2019 | 21403 | 0.130 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2016 | 133 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 236 | 0.130 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 306 | 0.130 |
Why?
|
| Sodium Acetate | 1 | 2014 | 2 | 0.120 |
Why?
|
| Multiple Sclerosis | 1 | 2016 | 132 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 163 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1593 | 0.120 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 66 | 0.120 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2013 | 17 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2018 | 617 | 0.110 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 37 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 284 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 507 | 0.110 |
Why?
|
| Antigens | 1 | 2013 | 90 | 0.110 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2013 | 11 | 0.110 |
Why?
|
| Heterozygote | 2 | 2013 | 174 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1030 | 0.110 |
Why?
|
| Choline | 1 | 2013 | 14 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3259 | 0.110 |
Why?
|
| AIDS Vaccines | 1 | 2013 | 7 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 286 | 0.110 |
Why?
|
| Middle Aged | 10 | 2019 | 21147 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2013 | 59 | 0.110 |
Why?
|
| Proteoglycans | 1 | 2013 | 103 | 0.110 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 383 | 0.110 |
Why?
|
| Dopamine Agents | 1 | 2013 | 56 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2014 | 239 | 0.110 |
Why?
|
| Cyclin B1 | 1 | 2012 | 7 | 0.110 |
Why?
|
| Malaria | 1 | 2013 | 26 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2013 | 282 | 0.110 |
Why?
|
| Brazil | 3 | 2018 | 48 | 0.110 |
Why?
|
| Exploratory Behavior | 1 | 2013 | 79 | 0.100 |
Why?
|
| Cell Differentiation | 2 | 2013 | 1034 | 0.100 |
Why?
|
| Locomotion | 1 | 2013 | 135 | 0.100 |
Why?
|
| Japan | 3 | 2017 | 68 | 0.100 |
Why?
|
| Cell Proliferation | 2 | 2013 | 1174 | 0.100 |
Why?
|
| Carcinoma | 1 | 2013 | 215 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 219 | 0.100 |
Why?
|
| Tremor | 1 | 2011 | 16 | 0.100 |
Why?
|
| Phenotype | 2 | 2013 | 947 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 800 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 929 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1040 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2016 | 7029 | 0.090 |
Why?
|
| Aged | 7 | 2016 | 14862 | 0.090 |
Why?
|
| Chromatography, Affinity | 1 | 2010 | 73 | 0.090 |
Why?
|
| Cell Line | 2 | 2015 | 1752 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 196 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 272 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 132 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2010 | 77 | 0.090 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2010 | 92 | 0.090 |
Why?
|
| Membrane Lipids | 1 | 2010 | 31 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 245 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2010 | 234 | 0.090 |
Why?
|
| Pyramidal Cells | 1 | 2010 | 79 | 0.090 |
Why?
|
| Rats, Wistar | 1 | 2010 | 371 | 0.080 |
Why?
|
| Oxaloacetic Acid | 1 | 2009 | 1 | 0.080 |
Why?
|
| Aminooxyacetic Acid | 1 | 2009 | 2 | 0.080 |
Why?
|
| Malates | 1 | 2009 | 5 | 0.080 |
Why?
|
| Genetic Association Studies | 3 | 2016 | 103 | 0.080 |
Why?
|
| Cell Compartmentation | 1 | 2009 | 41 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 87 | 0.080 |
Why?
|
| Polymorphism, Genetic | 3 | 2018 | 301 | 0.080 |
Why?
|
| Astrocytes | 1 | 2011 | 270 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2019 | 46 | 0.080 |
Why?
|
| Immunoradiometric Assay | 1 | 2008 | 3 | 0.080 |
Why?
|
| Lipids | 1 | 2010 | 298 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 92 | 0.080 |
Why?
|
| Neural Pathways | 1 | 2010 | 324 | 0.080 |
Why?
|
| Clozapine | 1 | 2008 | 46 | 0.080 |
Why?
|
| Haloperidol | 1 | 2008 | 95 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 290 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 954 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1447 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2008 | 173 | 0.080 |
Why?
|
| Cattle | 1 | 2008 | 475 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2010 | 682 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2008 | 114 | 0.070 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 415 | 0.070 |
Why?
|
| Amino Acids | 1 | 2007 | 131 | 0.070 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2007 | 65 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 55 | 0.070 |
Why?
|
| Enzyme Stability | 1 | 2006 | 30 | 0.070 |
Why?
|
| Glutamate Decarboxylase | 1 | 2006 | 18 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 200 | 0.070 |
Why?
|
| Macaca mulatta | 1 | 2006 | 77 | 0.070 |
Why?
|
| Osmolar Concentration | 1 | 2006 | 134 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 659 | 0.070 |
Why?
|
| Molecular Weight | 1 | 2006 | 358 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 2006 | 102 | 0.060 |
Why?
|
| Phylogeny | 1 | 2006 | 197 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 142 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1667 | 0.060 |
Why?
|
| Transfection | 1 | 2006 | 782 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2006 | 308 | 0.060 |
Why?
|
| Capsid Proteins | 1 | 2004 | 27 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 111 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 4848 | 0.050 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2018 | 2358 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2022 | 107 | 0.050 |
Why?
|
| Kidney | 1 | 2006 | 945 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 2 | 2013 | 129 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2021 | 54 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2020 | 6 | 0.050 |
Why?
|
| Esters | 1 | 2020 | 22 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 2004 | 446 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2019 | 56 | 0.040 |
Why?
|
| Water | 1 | 2020 | 230 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 89 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2019 | 78 | 0.040 |
Why?
|
| Pregnancy | 2 | 2016 | 2334 | 0.040 |
Why?
|
| Infusions, Subcutaneous | 1 | 2018 | 5 | 0.040 |
Why?
|
| Half-Life | 1 | 2018 | 96 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2017 | 10 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2018 | 111 | 0.040 |
Why?
|
| Tryptophan Oxygenase | 1 | 2016 | 2 | 0.040 |
Why?
|
| Immune Evasion | 1 | 2016 | 19 | 0.030 |
Why?
|
| Glutens | 1 | 2016 | 10 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2016 | 50 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2016 | 124 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 170 | 0.030 |
Why?
|
| Survival | 1 | 2014 | 22 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 5731 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Immunoglobulin Allotypes | 1 | 2014 | 82 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 91 | 0.030 |
Why?
|
| Cognition | 1 | 2017 | 513 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 742 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2013 | 100 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 2013 | 19 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 176 | 0.030 |
Why?
|
| Kenya | 1 | 2013 | 26 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3705 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 132 | 0.030 |
Why?
|
| Coinfection | 1 | 2013 | 30 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 280 | 0.030 |
Why?
|
| Mesoderm | 1 | 2013 | 231 | 0.030 |
Why?
|
| Homozygote | 1 | 2013 | 119 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 174 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2013 | 90 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 597 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2013 | 295 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2013 | 312 | 0.030 |
Why?
|
| Placenta | 1 | 2013 | 101 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 718 | 0.030 |
Why?
|
| HIV-1 | 1 | 2013 | 177 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 880 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2673 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 307 | 0.020 |
Why?
|
| Estonia | 1 | 2010 | 3 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 144 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7367 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 2093 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 2689 | 0.020 |
Why?
|
| Adolescent | 1 | 2014 | 8912 | 0.010 |
Why?
|